AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
274.83B
Market cap274.83B
Price-Earnings ratio
29.32
Price-Earnings ratio29.32
Dividend yield
1.72%
Dividend yield1.72%
Average volume
5.27M
Average volume5.27M
High today
$90.15
High today$90.15
Low today
$88.41
Low today$88.41
Open price
$89.86
Open price$89.86
Volume
3.45M
Volume3.45M
52 Week high
$90.27
52 Week high$90.27
52 Week low
$61.24
52 Week low$61.24

Stock Snapshot

AstraZeneca(AZN) stock is priced at $88.64, giving the company a market capitalization of 274.83B. It carries a P/E multiple of 29.32 and pays a dividend yield of 1.7%.

On 2025-11-20, AstraZeneca(AZN) stock traded between a low of $88.41 and a high of $90.15. Shares are currently priced at $88.64, which is +0.3% above the low and -1.7% below the high.

AstraZeneca(AZN) shares are trading with a volume of 3.45M, against a daily average of 5.27M.

During the past year, AstraZeneca(AZN) stock moved between $61.24 at its lowest and $90.27 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $61.24 at its lowest and $90.27 at its peak.

AZN News

Benzinga 3h
FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio

On Thursday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) for adult patients with neurofibromatosi...

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio
The Motley Fool 9h
Where Will IonQ Be in 10 Years?

A lot can happen for this quantum computing leader over the next decade. Ten years go by quickly. Duke University professors Chris Monroe and Jungang Kim found...

Where Will IonQ Be in 10 Years?
TipRanks 12h
AstraZeneca’s Koselugo Gains FDA Approval for Adult NF1 Treatment

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
16.1%
Sell
3.2%

More AZN News

TipRanks 1d
AstraZeneca treatment of multiple myeloma granted orphan designation

AstraZeneca (AZN) Pharmaceuticals’ treatment of multiple myeloma was granted FDA orphan designation status, according to a post to the agency’s website. Meet Y...

TipRanks 1d
AstraZeneca approves AstraZeneca’s Koselugo for adults with NF1

The Food and Drug Administration announced the approval of AstraZeneca’s (AZN) Koselugo for adults with neurofibromatosis type 1 who have symptomatic, inoperabl...

TipRanks 3d
Capital Group Increases Stake in AstraZeneca

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

TipRanks 4d
Clever Culture Systems Gains Industry Validation for APAS® Independence

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.